Brind.
  1. The FDA approved the Biologics License Application (BLA) for LEQEMBI IQLIK on August 30, 2025, involving companies headquartered in Cambridge and Tokyo.

Biogen and Eisai are involved in the LEQEMBI launch, with Biogen headquartered in Cambridge and Eisai in Tokyo.

3 reports, 2 independent Updated Jun 26
Gone quiet
Reports
3
Developments
4
Repetition
33%

New informationRepeats or wire copies

AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 2 outlets

Biogen and Eisai are involved in the LEQEMBI launch, with Biogen headquartered in Cambridge and Eisai in Tokyo.

Who's involved

What this event is mainly about
BiogenEisaiAustria

How it developed

Newest first. Tap a step to see who reported it.
  1. Biogen and Eisai partnered on Leqembi approval, and Salanersen received Breakthrough Therapy status.1 source
  2. EMA initially rejected Kisunla due to ARIA risks, affecting companies involved in Alzheimer's drug development.Sub-event
  3. Biogen shipped Leqembi to China for inventory optimization.Sub-event
  4. Biogen and Eisai are launching LEQEMBI in Austria.1 source

Keep exploring

Part of

The FDA approved the Biologics License Application (BLA) for LEQEMBI IQLIK on August 30, 2025, involving companies headquartered in Cambridge and Tokyo. All 2 developments

The entities involved

Related events

Coverage

Newest first; wire copies grouped
  • financialcontent.com
  • GlobeNewswireAustria and Germany to become the first markets in the European Union (EU) to launch LEQEMBI® (lecanemab) TOKYO and CAMBRIDGE, Mass., Aug. 25, 2025 (GLOBE NEWSWIRE) -- Eisai Co., Ltd. (Headquarters:
  • GlobeNewswireBiogen Announces $2 Billion Manufacturing Investment in North Carolina’s Research Triangle Park in Conjunction with its 30th Anniversary Investment builds on Biogen’s 30-year history of manufacturing